<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-08-23T21:50:28Z</responseDate><request verb="GetRecord" identifier="oai:riubu.ubu.es:10259/8072" metadataPrefix="qdc">https://riubu.ubu.es/oai/request</request><GetRecord><record><header><identifier>oai:riubu.ubu.es:10259/8072</identifier><datestamp>2023-11-22T01:05:32Z</datestamp><setSpec>com_10259_5827</setSpec><setSpec>com_10259_5086</setSpec><setSpec>com_10259_2604</setSpec><setSpec>col_10259_5828</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
<dc:title>TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status</dc:title>
<dc:creator>Herreros-Villanueva, Marta</dc:creator>
<dc:creator>Muñiz Rodríguez, Pilar</dc:creator>
<dc:creator>García Girón, Carlos</dc:creator>
<dc:creator>Cavia Saiz, Mónica</dc:creator>
<dc:creator>Coma del Corral, María J.</dc:creator>
<dcterms:abstract>Background: Although there have been many studies on the p73 gene, some of its functions still remain unclear.&#xd;
There is little research on the relationship between p73 gene transcription and its protein expression and the&#xd;
response to certain drugs such as oxaliplatin and cetuximab, which are drugs currently used in colorectal cancer.&#xd;
The purpose of this study was to evaluate the impact of TAp73 expression on oxaliplatin and cetuximab-based&#xd;
chemotherapy in colorectal cancer cell lines with different K-Ras and B-Raf mutational status.&#xd;
Methods: TAp73 was analyzed in three colorectal tumor cell lines HT-29, SW-480 and Caco-2. mRNA TAp73 was&#xd;
determined using Real time PCR; TAp73 protein by immunoblotting and cell viability was analyzed by the MTT&#xd;
method.&#xd;
Results: We found that mRNA and TAp73 protein were decreased in cells treated with oxaliplatin (in monotherapy&#xd;
or combined with cetuximab) when B-Raf is mutated. This was statistically significant and was also associated with&#xd;
higher cell viability after the treatment.&#xd;
Conclusions: Here, for the first time we report, that there is a signaling loop between B-Raf activation and p73&#xd;
function.&#xd;
Low expression of TAp73 in colorectal cancer cell lines with mutated B-Raf may be involved in the lack of response&#xd;
to oxaliplatin in monotherapy or combined with cetuximab.</dcterms:abstract>
<dcterms:dateAccepted>2023-11-21T08:59:34Z</dcterms:dateAccepted>
<dcterms:available>2023-11-21T08:59:34Z</dcterms:available>
<dcterms:created>2023-11-21T08:59:34Z</dcterms:created>
<dcterms:issued>2010-02</dcterms:issued>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>http://hdl.handle.net/10259/8072</dc:identifier>
<dc:identifier>10.1186/1479-5876-8-15</dc:identifier>
<dc:identifier>1479-5876</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>Journal of Translational Medicine. 2010, V. 8, n. 1</dc:relation>
<dc:relation>https://doi.org/10.1186/1479-5876-8-15</dc:relation>
<dc:rights>http://creativecommons.org/licenses/by/3.0/</dc:rights>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>Attribution 3.0 Unported</dc:rights>
<dc:publisher>Springer Nature</dc:publisher>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>